Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Strategic Alliance Partners

October 20, 2023

Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].

October 20, 2023

A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.

October 13, 2023

The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.

October 13, 2023

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

October 10, 2023

Closing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.

October 10, 2023

Julie R. Brahmer, MD, details emerging targets in non–small cell lung cancer and the outlook for the future of treatment.

October 06, 2023

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.

October 06, 2023

A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.

October 03, 2023

The focus turns to therapeutic strategies for treating MET exon 14 non–small cell lung cancer.

October 03, 2023

Experts on non–small cell lung cancer share their approaches to treating patients who have RET fusions and review updates on selpercatinib and pralsetinib.

September 29, 2023

The expert panel discusses the history of antibody-drug conjugates and explores their mechanisms of action.

September 29, 2023

A panel of cancer-treating specialists introduce the discussion with a broad overview of antibody-drug conjugates (ADCs).

September 26, 2023

Julie R. Brahmer, MD, and Joshua K. Sabari, MD, review recent data on entrectinib and larotrectinib for the treatment of patients with NSCLC with NTRK fusions.

September 26, 2023

The expert panel discusses factors that influence treatment decisions when choosing appropriate therapy for patients with ALK-rearranged NSCLC.

September 19, 2023

Experts on non–small cell lung cancer discuss recent data on brigatinib and lorlatinib for the treatment of patients with ALK rearrangements.

September 19, 2023

Luis Raez, MD, offers insights on how co-mutations in STK11 or KEAP1 impact the use of immunotherapies in KRAS G12C–mutant non–small cell lung cancer.

September 12, 2023

Joshua K. Sabari, MD, discusses adagrasib as a treatment of patients with NSCLC with KRAS G12C mutations, and provides insight on treating patients who have progressed on prior KRAS G12C inhibitors.

September 12, 2023

Expert panelists review the CodeBreaK trials focused on sotorasib in the treatment of patients with KRAS G12C-mutant non–small cell lung cancer.

September 05, 2023

Shared insight on the use of first-generation EGFR tyrosine kinase inhibitors and the role of immunotherapy in treating patients with NSCLC with uncommon EGFR mutations.

September 05, 2023

Julie R. Brahmer, MD, discusses treatment considerations when choosing between afatinib and osimertinib in patients with NSCLC with rare EGFR mutations.